• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ANKK1 Gene Record

  • Summary
  • Interactions
  • Claims
  • ANKK1 255239 Druggable Genome

    Alternate Names:

    255239
    ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1
    ANKK1
    DRD2
    PKK2
    608774
    21027
    ENSG00000170209
    OTTHUMG00000167715
    Q8NFD2
    SGK288
    ANKK1_HUMAN
    ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1 [SOURCE:REFSEQ_PEPTIDE;ACC:NP_848605]
    ANKYRIN REPEAT AND PROTEIN KINASE DOMAIN-CONTAINING PROTEIN 1
    PA134872551

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Interpro Acc IPR001245
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Interpro Type Domain
    Human Readable Name KINASE
    Uniprot Status Swiss-Prot
    Uniprot Evidence 1: Evidence at protein level
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Gene Biotype PROTEIN_CODING
    (4 More Sources)

    Gene Categories: Category Details

    KINASE
    SERINE THREONINE KINASE
    DRUGGABLE GENOME

    Publications:

    Tashiro M et al., 2014, Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients., Clin Chim Acta
    Sukasem C et al., 2016, Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders., J Clin Psychopharmacol
    López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
    Roke Y et al., 2013, The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys., Pharmacogenet Genomics
    Cabaleiro T et al., 2013, Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects., Hum Psychopharmacol
    Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J
    Yasui-Furukori N et al., 2008, Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients., Prog Neuropsychopharmacol Biol Psychiatry
    Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
    Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
    Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
    Levran O et al., 2013, Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction., Pharmacogenomics
    Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
    Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
    Stapleton JA et al., 2011, Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy., Pharmacogenet Genomics
    Munafò MR et al., 2009, Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial., Nicotine Tob Res
    Johnstone EC et al., 2004, Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch., Pharmacogenetics
    Mihara K et al., 2000, Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene., Psychopharmacology (Berl)
    Tomaz PR et al., 2015, CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy., Eur J Clin Pharmacol
    Choi HD et al., 2015, Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis., Int J Clin Pharmacol Ther
    David SP et al., 2007, Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials., Nicotine Tob Res
    David SP et al., 2007, Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation., Nicotine Tob Res
    Swan GE et al., 2005, Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR., Pharmacogenomics J
    Lerman C et al., 2003, Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial., Health Psychol
    Spellicy CJ et al., 2013, ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse., Pharmacogenet Genomics
    Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
    Comings DE et al., 1994, The dopamine D2 receptor gene: a genetic risk factor in substance abuse., Drug Alcohol Depend
    Ragia G et al., 2016, Association study of DRD2 A2/A1, DRD3 Ser9Gly, DβH -1021C>T, OPRM1 A118G and GRIK1 rs2832407C>A polymorphisms with alcohol dependence., Drug Metab Pers Ther
    Bolos AM et al., 1990, Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism., JAMA
    Blum K et al., 1990, Allelic association of human dopamine D2 receptor gene in alcoholism., JAMA
    Blum K et al., 1991, Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism., Alcohol
    Smith L et al., 2008, Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review., Am J Epidemiol
    Blomqvist O et al., 2000, Family-based study of DRD2 alleles in alcohol and drug dependence., Am J Med Genet
    Town T et al., 1999, Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency., Am J Med Genet
  • NEMONAPRIDE   ANKK1

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10823405


    Sources:
    PharmGKB

  • BUPROPION   ANKK1

    Interaction Score: 2.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26153084 25881752 18058343 17654295 15492764 14570538


    Sources:
    PharmGKB

  • ARIPIPRAZOLE   ANKK1

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18926547 18855532


    Sources:
    PharmGKB

  • RISPERIDONE   ANKK1

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26872113 23859574 23851570 20714340 18926547 18855532 18579277 18180754 18086475 17767146


    Sources:
    PharmGKB

  • CLOZAPINE   ANKK1

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26872113 23859574 23851570 20714340 18579277 18180754 18086475 17767146


    Sources:
    PharmGKB

  • OLANZAPINE   ANKK1

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26872113 23859574 23851570 23559402 20714340 18579277 18180754 18086475 17767146


    Sources:
    PharmGKB

  • ALCOHOL   ANKK1

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8033754 27447243 1979357 1969501 1839129 17989061 11054774 10490697


    Sources:
    PharmGKB

  • PROCHLORPERAZINE   ANKK1

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24360851


    Sources:
    PharmGKB

  • NICOTINE   ANKK1

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21540761 19273465 15077009


    Sources:
    PharmGKB

  • METHADONE   ANKK1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23651024


    Sources:
    PharmGKB

  • DISULFIRAM   ANKK1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23635803


    Sources:
    PharmGKB

  • HALOPERIDOL   ANKK1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27023437


    Sources:
    PharmGKB

  • Ensembl: ENSG00000170209

    • Version: 101_38

    Alternate Names:
    ANKK1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000170209

    • Version: 26-July-2011

    Alternate Names:
    ANKK1 Display Id
    ENSG00000170209 Ensembl Gene Id
    ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1 [SOURCE:REFSEQ_PEPTIDE;ACC:NP_848605] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: Q8NFD2

    • Version: 11-September-2012

    Alternate Names:
    ANKYRIN REPEAT AND PROTEIN KINASE DOMAIN-CONTAINING PROTEIN 1 Uniprot Protein Name
    Q8NFD2 Uniprot Accession
    ANKK1 Uniprot Gene Name

    Gene Info:
    Interpro Acc IPR001245
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Interpro Type Domain

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • PharmGKB: ANKK1

    • Version: 18-August-2020

    Alternate Names:
    PA134872551 PharmGKB ID

    Gene Info:

    Publications:
    Tashiro M et al., 2014, Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients., Clin Chim Acta
    Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J
    López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics

  • HingoraniCasas: ENSG00000170209

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000170209 Gene Symbol
    ANKK1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GO: ANKK1

    • Version: 01-February-2022

    Alternate Names:
    PKK2 GO Gene Synonym
    SGK288 GO Gene Synonym

    Gene Info:

    Gene Categories:
    SERINE THREONINE KINASE

    Publications:

  • dGene: ANKK1

    • Version: 27-Jun-2013

    Alternate Names:
    255239 Gene ID
    PKK2 dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, SERINE THREONINE KINASE

    Publications:

  • Pharos: ANKK1

    • Version: 01-February-2022

    Alternate Names:
    Ankyrin repeat and protein kinase domain-containing protein 1 Gene Name
    Q8NFD2 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21